anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Aseptic revisions are the most common reason for revision total knee arthroplasty (rTKA). Previous literature reports early periprosthetic joint infection (PJI) rates after aseptic rTKA to range from 3 to 9.4%. Intraosseous (IO) regional administration of vancomycin has previously been shown to produce high local tissue concentrations in primary and rTKA. However, no data exist on the effect of prophylactic IO vancomycin on early PJI rates in the setting of aseptic rTKA. The aim of this study was to determine the following: (1) what is the rate of early PJI during the first year after surgery in aseptic rTKA performed with IO vancomycin; and (2) how does this compare to previously published PJI rates after rTKA.
METHODS: A consecutive series of 117 cases were included in this study who underwent rTKA between January 2016 and March 2022 by 1 of 2 fellowship-trained adult reconstruction surgeons and received IO vancomycin at the time of surgery in addition to standard intravenous antibiotic prophylaxis. Rates of PJI at 3 months, 1 year, and the final follow-up were evaluated and compared to prior literature.
RESULTS: Follow-up at 3 months was available for 116 of the 117 rTKAs, with 1 lost to follow-up. The rate of PJI was 0% at 3 months postoperatively. Follow-up at 1 year was obtained for 113 of the 117 rTKAs, and the PJI rate remained 0%. The rate of PJI at the final follow-up of ≥ 1 year was 0.88% (95% confidence interval: -0.84 to 2.61). Previous literature reports PJI rates in aseptic rTKA to range from 3 to 9.4%.
CONCLUSIONS: Dual prophylactic antibiotics with IO vancomycin in conjunction with intravenous cephalosporins or clindamycin were associated with a substantial reduction in early PJI compared to prior published literature. These data supplement the early evidence about the potential clinical benefits of IO vancomycin for infection prevention in high-risk cases.
LEVEL OF EVIDENCE: Level III, therapeutic study.
In this single-arm study, patients will be treated with Artemether/lumefantrine, and the first, third and fifth doses of the drug will be given under the direct observation of the health workers. The patients will be followed-up for 42 days, on day 1, 2, 3, 7, 14, 21, 28 and 42 to assess the efficacy of the drug.
Coating compositions, coated articles comprising the coating compositions, and methods of making the coating compositions and the coated articles are provided. In some aspects, the coating composition is applied to a substrate having nitric oxide releasing properties. The coating composition may include a copolymer with a crosslinker that can be activated with mild UV light (about 345nm to 365nm) to avoid damaging the substrate when strong covalent bonds are created with the substrate. The copolymer may comprise hydrophilic repeat units, and in particular zwitterionic repeat units such as those containing phosphorylcholine groups. In some aspects, the coating composition is applied to a surface of a polymeric substrate, wherein the polymeric substrate has nitric oxide releasing properties. The coating composition and the coated article may have anti-fouling properties, anti-thrombogenic properties and/or anti-bacterial properties.
TRC105 is an experimental cancer drug designed to slow or stop the growth of tumors. It does this by preventing the growth of new blood vessels that feed these tumors. This drug is being used to test the safety and effectiveness to treat liver cancer that has not responded to standard therapy. TRC105 will be given as an intravenous infusion every two weeks.
In some embodiments, a proximity of a patient to a medical device (e.g., a medication dispensing device in which the patient removes a dose of medication that has been dispensed therefrom) may be determined, and a medical status associated with the patient is determined. Based on the determined proximity and the medical status, an alert, including a triggering element, is generated. The alert includes a first alarm type and a second, different alarm type. Upon activation of the triggering element, the medical device is monitored to confirm initiation and occurrence of a physical action (e.g., dispensing and removal of medication) using the medical device. Based on the monitoring, the medical status associated with the patient is updated. A patient device and/or interface may be utilized for the proximity determination and/or generating the alerts.
The patients to be included in this group will have applied isometric hand squeeze exercise, which lasted for twenty minutes a day, five days a week, before the PIVK procedure. On the fifth day, the patient's vital signs, skin color and skin turgor will be evaluated and recorded in the peripheral intravenous chemotherapy application registration form. Patients will be told how to use the stress ball 5 minutes before and during the PIVK procedure before the procedure. Patients will be taught to count from one to three and tighten and loosen the stress ball once, and they will be told to continue squeezing and loosening the stress ball in this way until the procedure is over. Focus their attention on the stress ball during the procedure.
All glinides, including PRANDIN, can cause hypoglycemia [see Adverse Reactions (6.1)]. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). 

Hypoglycemia can happen suddenly and symptoms may differ in each individual and change over time in the same individual. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions (7)], or in patients who experience recurrent hypoglycemia. 

Factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content), changes in level of physical activity, changes to co-administered medication [see Drug Interactions (7)], and concomitant use with other antidiabetic agents. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia [see Use in Specific Populations (8.6, 8.7)]. 

Patients should administer PRANDIN before meals and be instructed to skip the dose of PRANDIN if a meal is skipped. In patients who experience hypoglycemia, the dose of PRANDIN should be reduced [see Dosage and Administration (2.1)]. Patients and caregivers must be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.
The invention provides a method for culturing earthworms for infusing fructus lycii, salvia miltiorrhiza and earthworm wine and application of the earthworms. The method for culturing the earthworms comprises the steps of separately preparing fructus lycii powder, salvia miltiorrhiza powder and fermented wheat bran for culturing the earthworms, and removing internal dirt from the earthworms, thereby obtaining a purified product. A method for infusing the fructus lycii, salvia miltiorrhiza and earthworm wine comprises the step of infusing the purified product with 60-degree pure-grain liquor. The weight percent of earthworm protein in the fructus lycii, salvia miltiorrhiza and earthworm wine is 25.5% to 27.6%. By adopting fructus lycii and salvia miltiorrhiza to feed the earthworms as auxiliaries and then infusing the earthworms, the disadvantage that earthworm wine produced by adopting the conventional infusing methods has a rich offensive smell and is poor in taste is effectively eliminated, and the mind of medicine taking contradiction of patients is lowered. Already-crushed fructus lycii and salvia miltiorrhiza are added in stages during culturing, then, the earthworms gain the capacity for gradually accommodating to mixed feedstuff, the phenomenon of anorexia of the earthworms is eliminated, the cultured earthworms are big and fleshy in physical constitution, the culture cycle is short, and the protein content of the earthworms is high.
Subjects will be randomized in a 1:1 ratio to receive UDT (usual diabetes therapy) plus bromocriptine-QR. Following randomization subjects will be titrated to the maximum tolerated dose of the study drug over a four-week period. During these first 4 weeks, the daily dose of the study drug will be titrated up by one tablet (0.8 mg bromocriptine-QR) per day on a weekly basis until a maximal tolerated dose of at least two tablets (1.6 mg/day bromocriptine-QR) and no more than four tablets (3.2 mg/per day b-QR) is achieved. Subjects will be maintained at their maximum tolerated dose of between two to four tablets per day (1.6 to 3.2 mg bromocriptine-QR per day) for the duration of the study. Subjects will be seen at 4 weeks after randomization, at 12 weeks after randomization, and then at study end (week 24 or early termination).
A maximum dose of 300 mg/day is recommended for patients with severe renal impairment (CLCR≤30mL/min) and in patients with endstage renal disease. VIMPAT is effectively removed from plasma by hemodialysis. Following a 4-hour hemodialysis treatment, AUC of VIMPAT is reduced by approximately 50%. Therefore dosage supplementation of up to 50% following hemodialysis should be considered. In all renal impaired patients, the dose titration should be performed with caution. [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)]
Major improvements in cancer detection and treatment lead to longer life expectancy among cancer survivors. This may in turn lead to more late effects and many have to deal with long-term consequences of the disease and its' treatment. Returning to everyday life and to work is often an important part of returning to normal life for cancer survivors. There is increasing knowledge concerning late effects, but there is still lack of knowledge concerning the life of those experiencing late effects. There is a need for more knowledge about late effects' impact on the return to work prosess, physical activity and quality of life over time. Both quantitative and qualitative methods will be utilized. Standardized questionnaires will provide information on the effect of the intervention over time, in addition to quality of life over time. Sensewear armband will provide information about their physical activity over time. Official register data from the Norwegian Labour and Welfare Administration (the NAV administration) will provide us information about the work- and benefit situation through the whole follow-up period of 6-8 years. The register data include information about type of social benefits (sick-leave benefit, work assessment allowance (WAA), disability pension, unemployment benefit and retirement pension), as well as information about occupation, income and sick leave diagnosis. Focus group interviews will give us insight in the cancer survivors own experiences with quality of life over time, the transition from the specialist health services to the primary health care and the follow-up in the municipalities.
Intrahepatic cholangiocarcinoma (ICC) ranks as the second most common primary liver cancer, constituting 15%-20% of malignant liver tumors, with a rising incidence trend. Unlike hepatocellular carcinoma (HCC), ICC displays higher invasiveness and metastatic potential. Surgical resection remains the optimal treatment, yet many patients present with unresectable disease or metastasis, limiting surgical options. Chemotherapy, particularly the GC regimen, is standard for unresectable and metastatic ICC. Studies like ABC-02 have improved survival with GC chemotherapy compared to gemcitabine monotherapy. However, the median survival remains less than one year, highlighting the need for new treatments. Hepatic arterial infusion chemotherapy (HAIC), especially with fluoropyrimidine-based regimens, has shown promise in ICC treatment due to increased local drug concentration and reduced systemic toxicity. A combined approach of radiotherapy and HAIC with gemcitabine infusion may offer a hopeful strategy for locally advanced cholangiocarcinoma. However, clinical research on this combination is lacking as first-line therapy for unresectable ICC. Therefore, a single-center, single-arm study aims to assess this treatment approach's safety, efficacy, and molecular predictors. Improved HAIC delivery through modified percutaneous implantation provides a reliable pathway for effective treatment. In conclusion, exploring the synergistic effects of radiotherapy and HAIC in ICC could pave the way for more effective and personalized treatment strategies for this challenging cancer type.
PURPOSE:To provide a fruit body of Morchella esculenta, an extract of the fruit body of Morchella esculenta obtained by extracting the fruit body of Morchella esculenta with an organic solvent and a biofunctional food containing it as the active component. CONSTITUTION:An extract of the fruit body of Morchella esculenta with an organic solvent or a processed material (biofunctional food) of the fruit body is used for utilizing its excellent platelet aggregation inhibitory effect and blended with a carrier suitable for oral administration and permissible from the viewpoint of food sanitation, e.g. an organic or inorganic solid (e.g. starch, lactose or glucose) or liquid (e.g. edible alcohol) to form a biofunctional food exhibiting functions. This biofunctional food can be used in the form of a solid food, e.g. tablet, granule, capsule or extract or of a liquid food such as a solution.
The monoclonal antibody against herpes zoster comprises a heavy chain variable region and a light chain variable region, wherein the amino acid sequences of HCDR1, HCDR2 and HCDR3 in the heavy chain variable region are sequentially shown as SEQ ID NO: 9. SEQ ID NO: 10. SEQ ID NO: 11, the amino acid sequences of LCDR1, LCDR2 and LCDR3 in the light chain variable region are shown as SEQ ID NO: 12. SEQ ID NO: 13. SEQ ID NO: 14 is shown in the figure; or the amino acid sequences of HCDR1, HCDR2 and HCDR3 in the heavy chain variable region are sequentially shown as SEQ ID NO: 15. SEQ ID NO: 16. SEQ ID NO: 17, the amino acid sequences of LCDR1, LCDR2 and LCDR3 in the light chain variable region are shown as SEQ ID NO: 18. SEQ ID NO: 19. SEQ ID NO: shown at 20. Experiments prove that the antibody can be specifically combined with the herpes zoster recombinant protein, can neutralize the herpes zoster recombinant protein, and can be used for preparing related medicaments and herpes zoster detection products.
OBJECTIVE: To explore the relationship between gestational weight gain (GWG) and birth weight outcomes and establish suggested GWG patterns in early pregnancy weight loss women.
METHODS: This retrospective study was conducted based on the Beijing Birth Cohort Study from 2014 to 2021 and included 20 688 women. Weight change in early pregnancy was calculated using weight measurements within 16 weeks of gestation. Multivariable logistic regression was used to analyze the relationships of different GWG categories, based on the Chinese standard, and birth weight outcomes. The statistical-based approach was used to determine the optimal GWG ranges and weekly weight gain.
RESULTS: Compared to 3313 women who gained appropriate weight in early pregnancy, 2614 women who lost weight in the same period increased the risk of small for gestational age (SGA) (OR = 1.43, 95% CI: 1.14-1.80, P = 0.002). However, the relationship disappeared after adjusting for total GWG. Among the early pregnancy weight loss women, both excessive GWG and inadequate GWG were associated with adverse birth weight outcomes after adjusting for confounders. The suggested GWG range and rate were 11.0 ~ 16.0 kg and 0.46 to 0.67 kg/week from 16 weeks to delivery for women with normal body mass index (BMI) and weight loss in early pregnancy.
CONCLUSION: Weight loss in early pregnancy was not the independent risk factor of birth weight outcomes. GWG may offset the expected effects. To achieve optimal outcomes, women with normal BMI and weight loss in early pregnancy need to have a higher weight gain rate in mid-late pregnancy but similar total GWG ranges with the Chinese standard for general women.
Blood pressure (BP) measurements were taken every three weeks for 12 weeks. In accordance with their BP results, participants either stayed on their current medication or were started on the next higher regimen at the 3, 6, or 9 week visits. All participants began at 20 mg olmesartan, once daily for 3 weeks. The next higher regimen was olmesartan 40 mg, followed by olmesartan 40 mg + 12.5 mg hydrochlorothiazide, followed by olmesartan 40 mg + 25 mg of hydrochlorothiazide.
The present disclosure discloses a structurally novel tetrahydrofuro[2,3—b]indoline compound of formula I H, taz/\Rs | , a preparation method and an application thereof. The synthesis can be carried out under mild 5 conditions and at room temperature, the operation is simple and the yield is as high as 99%. The results of the anti— tumor cytotoxicity test of compounds Ia—Ih show that these compounds have certain inhibitory activity against cancer cells, including breast cancer cells MDArMB—23l and MCF—7, 10 osteosarcoma cancer cell U205, leukemia cell HL—60, lymphoma cell JeKo—l, HepG2 cell and. melanoma. cell .A375, etc. The compounds lb and. Id. have exhibited. significant inhibitory activity against JeKo—l, and the compound Ie has exhibited significant inhibitory activity against HL—60.
The invention relates to a technical field of natural plant toothpastes, and specifically relates to toothpaste containing sponge gourd and bitter gourd components. According to the invention, cooling, refreshing, blood circulation activating, meridian activating, and detoxifying effective components of sponge gourd, and blood nourishing, qi benefiting, and evil heat removing effective components of bitter gourd are added to a toothpaste substrate, such that the toothpaste is provided with functions of heat clearing and fire removing. With the toothpaste, symptoms such as gingival red swelling, gingival pain, gingival bleeding, toothache, and oral malodor caused by excessive oral heat can be effectively prevented and eliminated. The toothpaste provided by the invention is characterized by refreshing color and unique flavor. The toothpaste is slightly cool, slightly bitter, and slightly fragrant. The toothpaste is an optimal choice of mouth care.
Human papillomavirus (HPV) is an oncogenic DNA virus that plays a role in different cancer types. The aim of this study was to detect the prevalence and types of HPV and its relation with p16, EGFR and clinical findings in lung cancer. HPV and EGFR detection and genotyping of HPV were performed by polymerase chain reaction (PCR) and p16 by immunohistochemistry. Fifty lung cancer patients and seven patients with non-neoplastic lung disease were enrolled in this study. HPV was positive in 78% (39/50) of lung cancer cases. HPV 51 was the most frequent type, followed by HPV 16. Moreover, p16 was positive in 24% (12/50) of the cancer patients, and all of these patients were HPV-positive, while 27 HPV-positive patients showed no p16 expression. There was no relationship between HPV infection and p16 (p = 0.05), gender (p = 0.42), age (p = 0.38), or smoking history (p = 0.68). Although not statistically significant, the HPV prevalence was found to be higher in cancer patients compared to non-neoplastic patients. The prevalence of HPV in lung cancer varies across different studies, which may be due to differences in the detection methods, number of patients, geographic regions, and vaccination status. Further studies are necessary to understand the role of HPV in lung cancer pathogenesis.
Tumor angiogenesis is one of the typical hallmarks of tumor occurrence and development, and tumor neovascularization also exhibits distinct characteristics from normal blood vessels. As the number of cells and matrix inside the tumor increases, the biomechanical force is enhanced, specifically manifested as solid stress, fluid stress, stiffness, and topology. This mechanical microenvironment also provides shelter for tumors and intensifies angiogenesis, providing oxygen and nutritional support for tumor progression. During tumor development, the biomechanical microenvironment also emerges, which in turn feeds back to regulate the tumor progression, including tumor angiogenesis, and biochemical and biomechanical signals can regulate tumor angiogenesis. Blood vessels possess inherent sensitivity to mechanical stimuli, but compared to the extensive research on biochemical signal regulation, the study of the regulation of tumor neovascularization by biomechanical signals remains relatively scarce. Biomechanical forces can affect the phenotypic characteristics and mechanical signaling pathways of tumor blood vessels, directly regulating angiogenesis. Meanwhile, they can indirectly regulate tumor angiogenesis by causing an imbalance in angiogenesis signals and affecting stromal cell function. Understanding the regulatory mechanism of biomechanical forces in tumor angiogenesis is beneficial for better identifying and even taming the mechanical forces involved in angiogenesis, providing new therapeutic targets for tumor vascular normalization. Therefore, we summarized the composition of biomechanical forces and their direct or indirect regulation of tumor neovascularization. In addition, this review discussed the use of biomechanical forces in combination with anti-angiogenic therapies for the treatment of tumors, and biomechanical forces triggered delivery systems.
A total of 47 patients will be enrolled in this study. After screening, patients will receive intravenous drip of standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles. CT/MR of chest, upper and lower abdomen and pelvic MR will be performed before treatment and 2 weeks after the 3rd cycle chemotherapy. The objective response rate (ORR) (CR + PR) is evaluated by comparing with baseline based on RECISTv1.1. Radical surgery will be performed after NACT. According to the postoperative pathological results, the pathological complete remission rate (pCR) will be evaluated. The adverse events will be continuously monitored during treatment until 30 days after chemotherapy. Toxic adverse events is evaluated according to NCI-CTCAEv5.0 criteria.